The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus

Eun-Jung PARK; Hyungjin KIM; Seung-Min JUNG; Yoon-Kyoung SUNG; Han-Joo BAEK; Jisoo LEE.
Journal of Rheumatic Diseases ; : 4-21, 2020.
Artículo en Inglés | WPRIM | ID: wpr-786147

Documentos relacionados

  1. [Activity of ankylosing spondylitis in women within one year after childbirth].
  2. [Recommendations for diagnosis and treatment of ankylosing spondylitis].
  3. Top 100 cited articles on ankylosing spondylitis.
  4. TNF inhibitors have a protective role in the risk of dementia in patients with ankylosing spondylitis: Results from a nationwide study.
  5. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
  6. Cellular and molecular diversity in spondyloarthritis.
  7. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
  8. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
  9. Quality of life and therapeutic management of axial spondyloarthritis patients in Italy: a 12-month prospective observational study.
  10. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis.